ClinicalTrials.gg
RecruitingNCT05455138Updated Nov 18, 2023

Allografts in Surgery of the Main Arteries

An interventional study of Arterial bypass grafting in Critical Lower Limb Ischemia, sponsored by Ryazan State Medical University. Recruiting at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Ryazan State Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Registered 7 months after the study started (first participant enrolled Dec 2021, registered Jul 2022).
  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Atherosclerosis with a site in Russian Federation — 5 open to participants now, 5 under way, none of them phase 3. Atherosclerosis · Russian Federation.

Planned enrollment
14th of 27
200 · median 200
Started
2021
with 1 other
No phase
12 of 35
3 open now
Registered
32nd of 35
by date
Lead sponsor
2 of 35
Ryazan State Medical University

Among the 35 studies in Atherosclerosis with a site in Russian Federation, this one is the 14th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2021, is one of 12 with no phase, and was the 32nd registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

5 of the 35 studies in Atherosclerosis with a site in Russian Federation are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Atherosclerosis with a site in Russian Federation, or all of them as a file.
02

Study summary

The study will examine the results of the use of biological materials (allogeneic arterial grafts, allogeneic venous graft, autologous vein, biological bovine decellularized graft) as a bypass grafts for reconstructive interventions in patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease in the short-term and long-term postoperative periods. Histological analysis of allogeneic grafts will be carried out at various time points of graft preservation with a Roswell Park Memorial Institute 1640 cell medicum with 400mcg/ml gentamicin and 20mcg/ml fluconazole at a temperature of +4C.

The physical properties of allogeneic grafts from postmortem donors (tensile and tear strength) will be evaluated at various conservation time periods (1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks). Markers of endothelial dysfunction (IL-6, endothelin-1, 6-keto-prostaglandin F1alfa, eNOS) will be evaluated in patients with critical ischemia who undergo bypass procedures with arterial and venous allografts at various time points (before surgery, 7 days, 1 month, 3 months, 6 months, 1 year after).

Read the detailed description

The study will include 200 patients of similar age, gender, and ethnicity, who will be divided into four groups:

Group I: 50 patients who undergo arterial bypass procedures using autologous venous graft derived from great saphenous vein; Group II: 50 patients who undergo arterial bypass procedures using allogeneic venous grafts; Group III: 50 patients who undergo arterial bypass procedures using allogeneic arterial grafts; Group IV: 50 patients using biological bovine decellularized grafts.

Patients will be monitored for 2 years: at inclusion, and 1, 3, 6, 12, 18, and 24 months after bypass procedures.

The primary endpoint of the study will be mortality, i.e. death of the patient from any cause. Secondary endpoints of the study will be graft thrombosis and cardiovascular events such as myocardial infarction, acute coronary syndrome, transient ischemic attack, and stroke.

03

Conditions studied

  • Critical Lower Limb Ischemia

Keywords

  • Critical Lower Limb Ischemia
  • atherosclerosis
  • peripheral arterial disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • males or females over 18 years of age;
  • critical lower limb ischemia due to atherosclerotic peripheral arterial disease.

Exclusion criteria

Exclusion Criteria:

  • males or females less than 18 year of age;
  • decompensated concomitant pathology;
  • pregnancy or lactation.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Arterial bypass procedures using autologous venous graft

    Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using autologous venous graft

    Procedure: Arterial bypass grafting

  • Experimental
    Arterial bypass procedures using allogeneic venous graft

    Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using allogeneic venous graft

    Procedure: Arterial bypass grafting

  • Experimental
    Arterial bypass procedures using allogeneic arterial graft

    Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using allogeneic arterial graft

    Procedure: Arterial bypass grafting

  • Experimental
    Arterial bypass procedures using biologic bovine decellularized arterial graft

    Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using biologic bovine decellularized arterial graft

    Procedure: Arterial bypass grafting

Interventions

  • ProcedureArterial bypass grafting

    Arterial bypass grafting in patients with critical limb ischemia due to peripheral artery disease

06

What researchers measure

Primary outcomes

  1. Number of Participants with lethal outcomes

    The primary outcome measure is mortality rate

    Time frame: 24 months

Secondary outcomes

  1. Number of Participants with Graft thrombosis

    The secondary outcome measure is graft thrombosis

    Time frame: 24 months

  2. Myocardial infarction

    The secondary outcome measure is myocardial infarction

    Time frame: 1, 3, 6, 12, 18, and 24 months

  3. Number of Participants with Acute coronary syndrome

    The secondary outcome measure is acute coronary syndrome

    Time frame: 24 months

  4. Number of Participants with Stroke or transient ischemic attack

    The secondary outcome measure is stroke or transient ischemic attack

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
  • Ryazan State Medical University
    Ryazan, 390026, Russian Federation
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Dec 2025, 48 months after the start.

Of 178 non-industry interventional studies with no phase under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 48 months is above that.

Counting every sponsor, half of 198 studies reached it within 30 months; a quarter within 17 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2022
First posted
Jul 13, 2022
StartActual
Dec 1, 2021
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 1, 2025
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05455138
Lead sponsor
Ryazan State Medical University
Responsible party
Sponsor
First posted
Jul 13, 2022
Start date
Dec 1, 2021
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Nov 18, 2023

Study contacts

Igor Suchkov, PhD, DMedSc
Contact
suchkov_med@mail.ru
+7 (4912) 97-18-01
Igor Suchkov, PhD, DMedSc
principal investigator · Ryazan State Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion